Table 1.
Rates of new or worsening nephropathy and acute kidney injury among persons exposed to SGLT-2 inhibitors and active comparators
| Exposure Contrast | Alberta cohort | CPRD cohort | ||||||||
| Number of matched pairs | Mean survival time, years | Number of events | Rate of outcome events (per 1000 person-days) | 95% CI for rate | Number of matched pairs | Mean survival time, years | Number of events | Rate of outcome events (per 1000 person-days) | 95% CI for rate | |
| New or worsening nephropathy | ||||||||||
| SGLT-2 inhibitor | 7470 | 2.81 | 156 | 20.90 | 17.76 to 24.46 | 1635 | 3.00 | 32 | 15.34 | 10.50 to 21.66 |
| DPP4 inhibitor | 3.03 | 212 | 29.23 | 25.43 to 33.44 | 3.33 | 37 | 18.91 | 13.66 to 26.75 | ||
| SGLT-2 inhibitor | 7130 | 3.47 | 136 | 17.97 | 15.08 to 21.26 | 1440 | 3.17 | 28 | 15.07 | 10.01 to 21.78 |
| Sulfonylurea | 3.23 | 183 | 25.53 | 21.96 to 29.50 | 3.58 | 46 | 24.45 | 17.90 to 32.60 | ||
| SGLT-2 inhibitor | 413 | 3.43 | 15 | 26.22 | 14.68 to 43.24 | 509 | 3.57 | 7 | 9.58 | 3.85 to 19.75 |
| Thiazolidinedione | 2.26 | 9 | 20.78 | 9.50 to 39.44 | 1.94 | 18 | 28.30 | 16.78 to 44.74 | ||
| SGLT-2 inhibitor | 2769 | 2.82 | 57 | 18.98 | 14.38 to 24.59 | 684 | 2.97 | 20 | 20.15 | 12.31 to 31.13 |
| GLP1 receptor agonist | 2.66 | 54 | 21.84 | 16.40 to 28.50 | 4.12 | 15 | 17.60 | 9.85 to 29.02 | ||
| SGLT-2 inhibitor | 4459 | 3.44 | 123 | 24.86 | 20.66 to 29.66 | 961 | 4.30 | 28 | 11.74 | 7.80 to 16.97 |
| Insulin | 3.22 | 190 | 35.95 | 31.02 to 41.44 | 4.45 | 58 | 38.52 | 29.26 to 16.97 | ||
| Acute kidney injury | ||||||||||
| SGLT-2 inhibitor | 7470 | 1.99 | 42 | 5.57 | 4.01 to 7.52 | 1635 | 3.04 | 21 | 9.95 | 6.16 to 15.20 |
| DPP4 inhibitor | 2.97 | 63 | 8.56 | 6.58 to 10.96 | 3.37 | 22 | 11.40 | 7.14 to 17.26 | ||
| SGLT-2 inhibitor | 7130 | 3.56 | 36 | 4.71 | 3.30 to 6.52 | 1440 | 3.06 | 9 | 4.78 | 2.19 to 9.08 |
| Sulfonylurea | 2.31 | 45 | 6.20 | 4.52 to 8.29 | 4.12 | 23 | 12.02 | 7.62 to 18.03 | ||
| SGLT-2 inhibitor | 413 | 3.51 | 8 | 2.28 | 0.05 to 12.69 | 509 | 2.95 | 7 | 9.55 | 3.84 to 19.68 |
| Thiazolidinedione | 1.24 | s | 13.87 | 5.99 to 27.32 | 2.95 | 8 | 12.17 | 5.25 to 23.98 | ||
| SGLT-2 inhibitor | 2769 | 2.43 | 12 | 3.96 | 2.04 to 6.91 | 684 | 1.37 | s | 3.94 | 1.08 to 10.10 |
| GLP1 receptor agonist | 1.96 | 11 | 4.40 | 2.19 to 7.87 | 2.89 | 9 | 10.44 | 4.78 to 19.82 | ||
| SGLT-2 inhibitor | 4459 | 3.55 | 34 | 6.77 | 4.69 to 9.46 | 961 | 4.86 | 25 | 10.39 | 6.72 to 15.33 |
| Insulin | 3.34 | 71 | 13.13 | 10.25 to 16.56 | 4.77 | 38 | 24.38 | 17.25 to 33.45 | ||
s indicates person count <5.
CPRD, Clinical Practice Research Datalink; DPP4, dipeptidyl peptidase-4; GLP1, glucagon-like peptide-1; SGLT2-i, sodium-glucose cotransporter-2 inhibitors.